Methods for genome assembly and haplotype phasing
View Patent ↗The disclosure provides methods to assemble genomes of eukaryotic or prokaryotic organisms. The disclosure further provides methods for haplotype phasing and meta-genomics assemblies.
1. A method, comprising:
contacting a sample to a stabilizing agent, said sample comprising a nucleic acid molecule complexed to at least one nucleic acid binding protein;
cleaving the nucleic acid into a plurality of segments comprising at least a first segment and a second segment;
attaching the first segment and the second segment at a junction;
obtaining at least some sequence on each side of the junction to generate a first read pair;
mapping the first read pair to a set of contigs; and
determining, from the set of contigs, a presence of a structural variant or loss of heterozygosity in the sample.
2. The method of claim 1 , wherein the method further comprises assigning a variant in the set of contigs to a phase.
3. The method of claim 1 , wherein the method further comprises identifying a disease stage, a prognosis, or a course of treatment for the sample.
4. The method of claim 1 , wherein the method further comprises selecting a drug based on the presence of the variant.
5. The method of claim 1 , wherein the method further comprises identifying a drug efficacy for the sample.
6. The method of claim 1 , wherein the at least one nucleic acid binding molecule comprises a protein.
7. The method of claim 1 , wherein the stabilizing agent comprises formaldehyde.
8. The method of claim 1 , wherein attaching the first segment end to the second segment end to form an attachment product comprises ligating the first segment end to the second segment end.
9. The method of claim 1 , comprising attaching at least one of the first segment end and the second segment end to at least one affinity label prior to sequencing.
10. The method of claim 1 , comprising attaching at least one of the first segment end and the second segment end to a barcode.
11. A method, comprising:
contacting a sample to a stabilizing agent, said sample comprising a nucleic acid molecule complexed to at least one nucleic acid binding protein;
cleaving the nucleic acid into a plurality of segments comprising at least a first segment and a second segment;
attaching the first segment and the second segment at a junction;
obtaining at least some sequence on each side of the junction to generate a first read pair;
mapping the first read pair to a set of contigs; and
assigning a variant in the set of contigs to a phase.
12. The method of claim 11 , wherein the method further comprises determining, from the set of contigs, a presence of a structural variant or loss of heterozygosity in the sample.
13. The method of claim 11 , wherein the method further comprises identifying a disease stage, a prognosis, or a course of treatment for the sample.
14. The method of claim 11 , wherein the method further comprises selecting a drug based on the presence of the variant.
15. The method of claim 11 , wherein the method further comprises identifying a drug efficacy for the sample.
16. The method of claim 11 , wherein the at least one nucleic acid binding molecule comprises a protein.
17. The method of claim 11 , wherein the stabilizing agent comprises formaldehyde.
18. The method of claim 11 , wherein attaching the first segment end to the second segment end to form an attachment product comprises ligating the first segment end to the second segment end.
19. The method of claim 11 , comprising attaching at least one of the first segment end and the second segment end to at least one affinity label prior to sequencing.
20. The method of claim 11 , comprising attaching at least one of the first segment end and the second segment end to a barcode.
21. A method, comprising:
contacting a sample to a stabilizing agent, said sample comprising a nucleic acid molecule complexed to at least one nucleic acid binding protein;
cleaving the nucleic acid into a plurality of segments comprising at least a first segment and a second segment;
attaching the first segment and the second segment at a junction;
obtaining at least some sequence on each side of the junction to generate a first read pair;
mapping the first read pair to a set of contigs;
determining, from the set of contigs, a presence of a variant in the set of contigs; and
(i) identifying a disease stage, a prognosis, or a course of treatment for the sample; (ii) selecting a drug based on the presence of the variant; or (iii) identifying a drug efficacy for the sample.
22. The method of claim 21 , wherein the method further comprises determining, from the set of contigs, a presence of a structural variant or loss of heterozygosity in the sample.
23. The method of claim 21 , wherein the method further comprises assigning a variant in the set of contigs to a phase.
24. The method of claim 21 , wherein the at least one nucleic acid binding molecule comprises a protein.
25. The method of claim 21 , wherein the stabilizing agent comprises formaldehyde.
26. The method of claim 21 , wherein attaching the first segment end to the second segment end to form an attachment product comprises ligating the first segment end to the second segment end.
27. The method of claim 21 , comprising attaching at least one of the first segment end and the second segment end to at least one affinity label prior to sequencing.
28. The method of claim 21 , comprising attaching at least one of the first segment end and the second segment end to a barcode.